Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)
Conditions: Invasive Lobular Breast Carcinoma; ER+ Breast Cancer; HER2-negative Breast Cancer Interventions: Drug: Entrectinib; Drug: Letrozole; Drug: Goserelin Sponsors: Jules Bordet Institute; Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Endocrine Therapy | HER2 | Lobular Carcinoma | Neoadjuvant Therapy | Research | Study